Takeda Oncology

On #DressInBlueDay, we were?reminded how blue represents the color of hope, resilience and progress. This #ColorectalCancerAwarenessMonth and beyond, let’s continue to come together, support those affected by CRC and inspire hope for a brighter future. #CRCAM

By leading the conversation about the needs of patients with mCRC, we are helping people feel empowered to take a more active role in healthcare decisions.? ? We are committed to collaborating closely with the metastatic colorectal cancer (#mCRC) community to improve access to care, enhance patient quality of life and lead conversations that provide insight for us to continue working towards creating a brighter future with better health outcomes.? ? Read more about our ongoing commitment to meeting needs of patients with mCRC: https://lnkd.in/gy3gXtnR

Everyone in the #ColorectalCancer (CRC) community needs a strong network of support during diagnosis, treatment and beyond. For #ColorectalCancerAwarenessMonth, we asked advocates to share their perspectives on navigating a metastatic colorectal cancer (#mCRC) diagnosis and treatment. Swipe to see their thoughts on empowerment, self-advocacy, and how patient advocacy groups can support. #CRCAM

Advocacy and empowerment are critical to the metastatic colorectal cancer (#mCRC) community.? We were honored to host the mCRC community in an educational discussion on the unmet needs of people living with mCRC and disparities faced by Black and Hispanic communities, based on the results from our U.S. patient survey. During the event, held at this year’s American Society of Clinical Oncology (ASCO)’s Gastrointestinal Symposium, we shared findings from our recent patient survey and discussed how advocates can support patients to make more informed care decisions and take a more active role in their treatment plan. Thank you to everyone for their participation and to our partners, BLKHLTH, COLONTOWN, Colorectal Cancer Alliance, Family Reach and Manish Shah, M.D., for their unwavering commitment to addressing unmet needs in the mCRC community.?? ? #CRC #crcsm #GI25

#NEWS: We are pleased to announce with our partner Protagonist Therapeutics that the Phase?3 VERIFY trial for people with polycythemia vera (PV) met its primary endpoint. Our commitment to the hematologic cancer community is steadfast, and we look forward to future milestones that we hope will result in important advancements for patients. Read more here: https://lnkd.in/eMBzta98

Advocating for yourself when making treatment decisions during a metastatic colorectal cancer (#mCRC) diagnosis is crucial.? ? Our U.S. patient survey done with advocacy partners, BLKHLTH, Family Reach, COLONTOWN and Colorectal Cancer Alliance, shined a light on the factors impacting treatment decisions for people with mCRC. Read the results presented at the ASCO GI Symposium: https://lnkd.in/gpaFQzG3 ? Thank you to our advocacy partners and our Head of Patient Advocacy and Engagement, Scott Campbell, for your dedication to mCRC patients.? ? #CRC #crcsm #GI25

Today on #WorldCancerDay and every day, we are #UnitedByUnique with the global #cancer community. Each person’s journey is different and spans beyond the diagnosis, making providing support beyond medicine essential. Learn more: https://lnkd.in/ehMDNxaU

Navigating the challenges that come with a metastatic colorectal cancer (#mCRC) diagnosis can be daunting.?? ? Our U.S. patient survey done in collaboration with BLKHLTH, Family Reach, COLONTOWN and Colorectal Cancer Alliance revealed the factors that impact decisions throughout the cancer journey, many of which disproportionately affect those within Black and Hispanic communities.? ? Read the results presented at the American Society of Clinical Oncology (ASCO)’s Gastrointestinal Symposium here: https://lnkd.in/gpaFQzG3 ? #CRC #crcsm #GI25

Join us at the American Society of Clinical Oncology (ASCO)’s Gastrointestinal Symposium. We’ll present results from our U.S. patient survey in partnership with leading advocacy organizations to identify some of the most pressing needs concerning disease and treatment navigation for people with metastatic colorectal cancer (#mCRC).?? ?? We hope to see you there! Find more details on #GI25: https://lnkd.in/gKTHHUbZ #CRC #crcsm??

At Takeda, we’re committed to helping improve care and quality of life for patients in need of new treatment options. Our licensing agreement with Keros Therapeutics will help accelerate development of a therapy designed to treat anemia associated with?certain hematologic cancers, including?#MyelodysplasticSyndromes (MDS) and #Myelofibrosis (MF). This late-stage investigational therapy has the potential to improve outcomes for people with #BloodCancers by targeting key pathways in blood cell production. Hear more about this partnership from Teresa Bitetti?and Phuong Khanh (PK) Morrow in the video below.